Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $30.40

Key Points

• 4D Molecular Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analysts, with the average 12-month target price set at $30.40.
• The company reported (-$0.98) earnings per share, missing analysts' expectations, and had a negative net margin of 594,375.81% in its latest earnings report.
• Institutional investors own 99.27% of the company's stock, indicating strong institutional interest in 4D Molecular Therapeutics.

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $30.40.

A number of brokerages recently issued reports on FDMT. The Goldman Sachs Group lowered their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Roth Capital lowered their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, Barclays lowered their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock remained flat at $7.26 during trading hours on Thursday. 661,151 shares of the stock traded hands, compared to its average volume of 881,773. The stock has a 50-day simple moving average of $4.68 and a 200 day simple moving average of $4.13. The stock has a market cap of $339.04 million, a PE ratio of -2.05 and a beta of 2.83. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $17.41.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. Research analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Decheng Capital LLC raised its position in shares of 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock valued at $2,228,000 after buying an additional 2,165 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of 4D Molecular Therapeutics by 11.7% in the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock valued at $81,000 after buying an additional 2,284 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock valued at $247,000 after buying an additional 2,925 shares during the last quarter. ProShare Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 30.1% in the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock valued at $91,000 after buying an additional 3,783 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its position in shares of 4D Molecular Therapeutics by 35.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company's stock valued at $61,000 after buying an additional 4,295 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.